Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation. Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two s...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, José Diogo S., Zuardi, Antonio W., Guimarães, Francisco S., Osório, Flávia de Lima, Loureiro, Sonia Regina, Campos, Alline Cristina, Hallak, Jaime E. C., Dos Santos, Rafael G., Machado Silveira, Isabella Lara, Pereira-Lima, Karina, Pacheco, Julia Cozar, Ushirohira, Juliana Mayumi, Ferreira, Rafael Rinaldi, Costa, Karla Cristinne Mancini, Scomparin, Davi Silveira, Scarante, Franciele Franco, Pires-Dos-Santos, Isabela, Mechoulam, Raphael, Kapczinski, Flávio, Fonseca, Benedito A. L., Esposito, Danillo L. A., Andraus, Maristela Haddad, Crippa, José Alexandre S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574068/
https://www.ncbi.nlm.nih.gov/pubmed/36263136
http://dx.doi.org/10.3389/fphar.2022.856846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574068/
https://www.ncbi.nlm.nih.gov/pubmed/36263136
http://dx.doi.org/10.3389/fphar.2022.856846

Ejemplares similares